| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 312.06 | 52.9% | 7.4% |
| Total Income | 314.38 | 52.3% | 4.3% |
| Expenditure | 283.54 | 48.8% | 3.1% |
| PBT | 30.85 | 93.4% | 248.8% |
| Net Profit | 22.93 | 78.3% | 441.9% |
| OPM | 12.72% | 1.18pp | 6.56pp |
| NPM | 7.29% | 43.81pp | 5.89pp |
| EPS | 15.53 | 104.1% | 424.7% |
Growth beating guidance, order book strong, but WC stretched
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Q2 standalone beat guidance (52% revenue, 77% PAT vs 25-30% growth guidance). H1 32% growth confirms trajectory. However, consolidated YoY is 7.4% due to deconsolidation of loss-making U.K. entity in Q1—management disclosed this but relies on standalone metrics.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Standalone revenue beat guidance (52% vs 25-30% target) with strong order book (₹2,000 Cr, 38% YoY) and major defense/space wins signal multi-year growth potential. Key risk: working capital strain (inventory ₹540 Cr) and supply chain lead-time extensions could constrain near-term execution.
₹312.1 Cr
Revenue · +52% YoY₹22.9 Cr
Reported PAT · +77% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 standalone revenue ₹312 Cr, 52% YoY growth
METQ2 delivered revenue 312.1 Cr, standalone growth 52% YoY confirmed
Q2 PAT ₹23 Cr, 77% YoY standalone growth
METQ2 delivered PAT 22.9 Cr, standalone growth 77% YoY confirmed
Q2 EBITDA margin 12.69%, up 87 bps YoY
METQ2 delivered OPM 12.7%, aligns with claimed EBITDA margin
Order book ₹2,000 Cr as of Sept 2026, 38% YoY growth
UnverifiedLarge order book stated, 38% growth claimed but absolute amount not independently verified
FY27 India revenue growth target 25%-30% achievable
METQ2 standalone growth 52% already exceeds full-year 25-30% guidance; H1 standalone growth 32% confirms delivery on track
Semiconductor business $45-50M visibility in next 1-2 years
OVERSTATEDH1 FY27 delivery ~₹85-90 Cr (~$10-11M USD); $45-50M is ~4.5x current run rate, ambitious but mechanism not detailed
Earnings quality
What changed since the last call
Semiconductor target upgraded
UpgradePrior guidance $25-30M USD run rate in 1-2 years; now claiming $45-50M visibility. Upper end raised 67%. Driven by AI datacenter and industrial demand, but ramp is steep.
Order book depth increased
UpgradeOrder book ₹2,000 Cr as of Sept 2026 (38% YoY growth). Prior call implied ~₹1,450 Cr baseline. 25-30 month execution cycle provides strong visibility.
EMS acceleration faster than expected
UpgradeEMS grew 41% Q2 (vs prior guidance ~25-30% blended). Three new marquee customer wins in transportation, industrial, defense. Semiconductor inside EMS is outpacing.
Margin guidance tone softened slightly
NeutralPrior: 13%+ target. Now: 12.5%-13% range. Marginal hedging due to product mix (lower-margin BTS programs) and supply chain cost inflation, but not a cut.
FY27 revenue growth reaffirmed at 25-30%
NeutralSame as prior. Q2 beat (52%) makes full-year 25-30% look conservative, but H2 will test order book execution.
The Q&A
Analysts pressed on margins (Ankit), capacity (Vayun), working capital (Vayun), and execution risk. Mgmt held firm on order book and execution but stayed measured on margin uplift (20%-22% BTS, 13% blended), acknowledging product mix pressure. Q&A revealed willingness to invest capex (₹50-70 Cr) to expand system-level capacity. No major pushback on near-term targets; questions mostly structural.
Revenue guidance & margins — Ankit Babel, Subhkam Ventures
PartialWe don't give specific annual guidance, but confidence is high at 25%-30% medium-term growth. BTS margins 20%-22% range; variation is product-mix driven. Program-by-program fluctuation is normal.
BTS spillover & H2 growth — Tanay Shah, DAM Capital
PartialPerformance reflects higher execution and order book activity, not one-time spike. H2 should also be strong; we expect growth to continue but with quarterly variation. No specific H2 guidance.
Capacity & execution — Vayun Jain, Bajaj Alternative Investment
AnsweredOrders execute over 2-2.5 years. No short-term capacity constraint on production; we're adding engineering bench for design. Capex plan (₹50-70 Cr FY28) for new BTS facility to expand system-level capability.
Working capital & inventory — Vayun Jain, Bajaj Alternative Investment
AnsweredInventory is growth + supply chain constraint driven. ~50% covered by customer prepaids. Supply-chain: lead times on PCBs, memory, controllers extended 40-50 weeks vs 8-12 weeks normal. Capex & WC working capital are priorities for QIP use.
Semiconductor guidance & opportunity — Tanay Shah, DAM Capital
PartialSegment growing aggressively. We've exceeded initial $25-30M target estimate. AI data center & industrial demand strong. Visibility to $45-50M in 1-2 years through mix improvement and new product lines.
EMS new customers — Tanay Shah, DAM Capital
AnsweredTransportation OEM is large global Tier 1 doing platform door/braking systems electronics; they're localizing to India. German industrial (metrology) & Middle East defense are design-led opportunities. Each could be $10M+ engagement over 2-3 years once ramped.
Global BTS export order — Nirali Gopani, Unique PMS
DodgedStrategic objective: get system-level export orders from foreign defense OEMs. We've won initial design contracts; one Middle East customer is design-phase now. Early discussions with European OEM also underway. Too early to quantify large TAM; timelines still hazy but commitment clear.
Defense/space headroom & export strategy — Pranav Bastawala, Private Investor
PartialDefense/space is moving toward private-company integration. Satellites, payloads = thousands of crores opportunity. We're committing to assembly integration facility for full satellites. Defence 60/40 split with space over next 2-3 years likely. Very confident but timelines hazy on this front.
BTS export TAM & execution — Ritu Rawat, Private Investor
AnsweredGlobal OEM, electronic warfare ELINT subsystem for naval applications. Core tech is reusable across platforms. Expect repeat orders from this customer; opens doors for other platforms. ₹30 Cr order sets us up for bigger subsequent engagements.
Guidance
FY27 standalone revenue growth 25%-30%, could be closer to 30%
HighMedium-term objective maintained. Q2 actual 52% standalone growth exceeds guidance; H1 32% growth on track for full-year target.
Order book ₹2,000 Cr as of Sept 2026; 25-30 month execution cycle provides multi-quarter visibility
HighOrder book up 38% YoY. BTS ₹959 Cr, EMS ₹~1,000+ Cr estimated. Execution on track with major wins.
EBITDA margins 12.5%-13% range; company targets breaching 13% mark over medium term
MediumQ2 achieved 12.69%, H1 12.11%. BTS margins constrained at 20-22% (product mix driven). Full-company target 13% credible but near-term product mix headwinds acknowledged.
Long-term margin trajectory: 14%-15% in next 3-4 years
MediumDependent on higher-margin EMS programs ramping and design-led manufacturing scaling. Supply-chain cost inflation is near-term headwind.
Aerospace capex ₹50-70 Cr planned for FY28 for new BTS facility
HighIntent to establish system-level capabilities & increase capacity for order book execution. Committed investment signal.
Risks the call surfaced
Supply chain constraints
HighPCB, memory, controller lead times extended to 40-50 weeks (from 8-12 weeks normal). Inventory ₹540 Cr reflects buildup to de-risk. Cost inflation on memory devices reducing margins.
Order book execution risk
High₹2,000 Cr order book (~6.4x quarterly revenue) over 25-30 month execution cycle. Single large export order (₹30 Cr EW) is 9.6% of Q2 revenue. BTS programs execute slowly; delay or rework could impact PAT.
Working capital deterioration
MediumNet working capital cycle extended to 136 days (from prior <130 days). Inventory ₹540 Cr is structural drag. Receivable days improved to 106 days but growth in absolute receivables (INR amounts not disclosed). Debt limit increased ₹500 Cr to ₹1,000 Cr post-Q2 to support WC.
Margin compression risk
MediumBTS margin constrained at 20%-22% due to program mix (higher material cost programs). Supply chain inflation on components. EMS margins healthier but driven by lower-margin semiconductor mix initially. To reach 13% company target requires careful mix management.
Semiconductor ramp execution
MediumH1 FY27 delivery ~₹85-90 Cr (~$10-11M USD). Management targets $45-50M run rate in 1-2 years (4.5x jump). Mechanism is primarily AI datacenter & industrial demand, but no concrete large contracts yet mentioned. Ramp timing risk is high.
Customer concentration on large contracts
Medium₹30 Cr EW export order is 9.6% of Q2 revenue. ₹51 Cr air nav is 16.3% of Q2. Concentration risk exists even with multiple customers; program delays directly impact PAT (given 20-22% BTS margin, a ₹10 Cr miss = ₹2-2.2 Cr PAT miss).
Deconsolidation & overseas exposure
LowU.K. subsidiary deconsolidated Q1 FY27 (was SPV only, loss-making). Removes ~₹85 Cr revenue exposure & ~₹8-10 Cr loss. Consolidated metrics now ~7% growth but standalone 52%, creating reporting inconsistency. Deconsolidation is positive (removes drag) but creates one-time metric shift.
Management
Score 7/10. Clear on operational metrics (order book, margin ranges, segment growth) but measured on forward guidance (no specific quarterly/annual numbers). Transparent on supply chain challenges & working capital pressure. Disclosed deconsolidation upfront. Beat H1 guidance (32% growth vs 25-30% FY27 target). Q2 standalone 52% growth ahead of plan. Major wins in defense/space/semiconductor validate execution. Capex commitment (₹50-70 Cr FY28) signals seriousness on capacity.
1 · Q3-Q4 FY27
Ramp major defense/space orders (₹30 Cr EW, ₹51 Cr air nav, satellite)
2 · FY28
BTS facility capex (₹50-70 Cr) establishes system-level capabilities, prepares for next phase
3 · Next 1-2Y
Semiconductor business scales to $45-50M run rate; new EMS customer production ramps
Key risk: working capital strain (inventory ₹540 Cr) and supply chain lead-time extensions could constrain near-term execution.